VNRX stock jumps 34% on early stage cancer detection

VolitionRx (VNRX) shares surged over 34% pre-market after the company announced proof-of-concept data for its new liquid biopsy method. The test achieved over 95% sensitivity for early-stage I and II cancers with 95% specificity in a blinded validation cohort. This breakthrough drove retail sentiment to bullish with extremely high message volumes.